Global Tetrahydrocannabinol Market

Tetrahydrocannabinol Comprehensive Study by Application (Chronic Pain, Mental Disorders, Arthritis, Migraine, Cancer, Other), Distribution Channel (Hospital Pharmacy, Dispensaries, Online Pharmacy) Players and Region - Global Market Outlook to 2026

Tetrahydrocannabinol Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Tetrahydrocannabinol is referred to as principal active ingredients in marijuana. In the United States, marijuana still remains the most repeatedly abused illicit drug, though its popularity appears to cycle, trending up and down over decades. THC is classified as a mild sedative at low doses and a hallucinogen at high doses. According to the National Institute on Drug Abuse (NIDA), it acts much like the cannabinoid chemicals made naturally by the body. THC attaches to these receptors and activates them and affects a person's memory, pleasure, coordination, movements, thinking, concentration, and sensory and time perception, according to NIDA. Its anti-emetic properties (inhibits vomiting) are particularly useful in the treatment of cancer patients on chemotherapy. Also, as THC increases the appetite and reduces the vomit response, it is starting to be used in the treatment of anorexia and other eating disorders.
This growth is primarily driven by Growing Research and Development Activities and High Public and Private Investments in Research and Developments.

Globally, a noticeable market trend is evident Health Safety in Cannabis Products . The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as MedReleaf Corporation (Canada), Aurora Cannabis Inc. (Canada), BOL Pharma (Israel), Tilray (Canada), Medreleaf Corporation (Canada), Aurora Cannabis, Inc. (Canada), Green Relief Inc. (Canada), Canopy Growth Corporation (Canada), Insys Therapeutics, Inc. (United States) and Aphria, Inc. (Canada) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 22 Jan 2019, Tilray, Inc. has announced a definitive agreement with Natura Naturals Holdings Inc., the parent company of a licensed cultivator of cannabis. Due to the agreement, Tilray will obtain Natura’s 662,000 square-foot greenhouse cultivation facility, of which 155,000 square-feet are currently licensed, and all subsequent cannabis output from this facility.

Regulatory Insights:
FDA has concluded that THC and CBD products are excluded from the dietary supplement definition under section 201(ff)(3)(B) of the FD&C Act [21 U.S.C. § 321(ff)(3)(B)]. Under that provision, if a substance (such as THC or CBD) is an active ingredient in a drug product that has been approved under section 505 of the FD&C Act [21 U.S.C. § 355], or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are excluded from the definition of a dietary supplement.

Market Drivers
  • Growing Research and Development Activities
  • High Public and Private Investments in Research and Developments

Market Trend
  • Health Safety in Cannabis Products
  • Legalization of Medicinal Cannabis in Various Economies

Restraints
  • Extreme consumption Leads to The Risk of Heart Attack

Opportunities
Huge Demand due to Use in Healthcare Industry and Emerging Demand from Economies
Challenges
Straighten Government Regulations

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Tetrahydrocannabinol Study Sheds Light on
— The Tetrahydrocannabinol Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Tetrahydrocannabinol industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Tetrahydrocannabinol industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Chronic Pain
  • Mental Disorders
  • Arthritis
  • Migraine
  • Cancer
  • Other
By Distribution Channel
  • Hospital Pharmacy
  • Dispensaries
  • Online Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Research and Development Activities
      • 3.2.2. High Public and Private Investments in Research and Developments
    • 3.3. Market Challenges
      • 3.3.1. Straighten Government Regulations
    • 3.4. Market Trends
      • 3.4.1. Health Safety in Cannabis Products
      • 3.4.2. Legalization of Medicinal Cannabis in Various Economies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tetrahydrocannabinol, by Application, Distribution Channel and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Tetrahydrocannabinol (Value)
      • 5.2.1. Global Tetrahydrocannabinol by: Application (Value)
        • 5.2.1.1. Chronic Pain
        • 5.2.1.2. Mental Disorders
        • 5.2.1.3. Arthritis
        • 5.2.1.4. Migraine
        • 5.2.1.5. Cancer
        • 5.2.1.6. Other
      • 5.2.2. Global Tetrahydrocannabinol by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacy
        • 5.2.2.2. Dispensaries
        • 5.2.2.3. Online Pharmacy
      • 5.2.3. Global Tetrahydrocannabinol Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Tetrahydrocannabinol (Volume)
      • 5.3.1. Global Tetrahydrocannabinol by: Application (Volume)
        • 5.3.1.1. Chronic Pain
        • 5.3.1.2. Mental Disorders
        • 5.3.1.3. Arthritis
        • 5.3.1.4. Migraine
        • 5.3.1.5. Cancer
        • 5.3.1.6. Other
      • 5.3.2. Global Tetrahydrocannabinol by: Distribution Channel (Volume)
        • 5.3.2.1. Hospital Pharmacy
        • 5.3.2.2. Dispensaries
        • 5.3.2.3. Online Pharmacy
      • 5.3.3. Global Tetrahydrocannabinol Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Tetrahydrocannabinol (Price)
  • 6. Tetrahydrocannabinol: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. MedReleaf Corporation (Canada)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Aurora Cannabis Inc. (Canada)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BOL Pharma (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Tilray (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Medreleaf Corporation (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Aurora Cannabis, Inc. (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Green Relief Inc. (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Canopy Growth Corporation (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Insys Therapeutics, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Aphria, Inc. (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Tetrahydrocannabinol Sale, by Application, Distribution Channel and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Tetrahydrocannabinol (Value)
      • 7.2.1. Global Tetrahydrocannabinol by: Application (Value)
        • 7.2.1.1. Chronic Pain
        • 7.2.1.2. Mental Disorders
        • 7.2.1.3. Arthritis
        • 7.2.1.4. Migraine
        • 7.2.1.5. Cancer
        • 7.2.1.6. Other
      • 7.2.2. Global Tetrahydrocannabinol by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacy
        • 7.2.2.2. Dispensaries
        • 7.2.2.3. Online Pharmacy
      • 7.2.3. Global Tetrahydrocannabinol Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Tetrahydrocannabinol (Volume)
      • 7.3.1. Global Tetrahydrocannabinol by: Application (Volume)
        • 7.3.1.1. Chronic Pain
        • 7.3.1.2. Mental Disorders
        • 7.3.1.3. Arthritis
        • 7.3.1.4. Migraine
        • 7.3.1.5. Cancer
        • 7.3.1.6. Other
      • 7.3.2. Global Tetrahydrocannabinol by: Distribution Channel (Volume)
        • 7.3.2.1. Hospital Pharmacy
        • 7.3.2.2. Dispensaries
        • 7.3.2.3. Online Pharmacy
      • 7.3.3. Global Tetrahydrocannabinol Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Tetrahydrocannabinol (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tetrahydrocannabinol: by Application(USD Million)
  • Table 2. Tetrahydrocannabinol Chronic Pain , by Region USD Million (2015-2020)
  • Table 3. Tetrahydrocannabinol Mental Disorders , by Region USD Million (2015-2020)
  • Table 4. Tetrahydrocannabinol Arthritis , by Region USD Million (2015-2020)
  • Table 5. Tetrahydrocannabinol Migraine , by Region USD Million (2015-2020)
  • Table 6. Tetrahydrocannabinol Cancer , by Region USD Million (2015-2020)
  • Table 7. Tetrahydrocannabinol Other , by Region USD Million (2015-2020)
  • Table 8. Tetrahydrocannabinol: by Distribution Channel(USD Million)
  • Table 9. Tetrahydrocannabinol Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 10. Tetrahydrocannabinol Dispensaries , by Region USD Million (2015-2020)
  • Table 11. Tetrahydrocannabinol Online Pharmacy , by Region USD Million (2015-2020)
  • Table 12. South America Tetrahydrocannabinol, by Country USD Million (2015-2020)
  • Table 13. South America Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 14. South America Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 15. Brazil Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 16. Brazil Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 17. Argentina Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 18. Argentina Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 19. Rest of South America Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 20. Rest of South America Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 21. Asia Pacific Tetrahydrocannabinol, by Country USD Million (2015-2020)
  • Table 22. Asia Pacific Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 23. Asia Pacific Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 24. China Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 25. China Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 26. Japan Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 27. Japan Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 28. India Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 29. India Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 30. South Korea Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 31. South Korea Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 32. Taiwan Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 33. Taiwan Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 34. Australia Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 35. Australia Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 36. Rest of Asia-Pacific Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 37. Rest of Asia-Pacific Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 38. Europe Tetrahydrocannabinol, by Country USD Million (2015-2020)
  • Table 39. Europe Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 40. Europe Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 41. Germany Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 42. Germany Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 43. France Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 44. France Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 45. Italy Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 46. Italy Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 47. United Kingdom Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 48. United Kingdom Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 49. Netherlands Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 50. Netherlands Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 51. Rest of Europe Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 52. Rest of Europe Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 53. MEA Tetrahydrocannabinol, by Country USD Million (2015-2020)
  • Table 54. MEA Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 55. MEA Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 56. Middle East Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 57. Middle East Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 58. Africa Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 59. Africa Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 60. North America Tetrahydrocannabinol, by Country USD Million (2015-2020)
  • Table 61. North America Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 62. North America Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 63. United States Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 64. United States Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 65. Canada Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 66. Canada Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 67. Mexico Tetrahydrocannabinol, by Application USD Million (2015-2020)
  • Table 68. Mexico Tetrahydrocannabinol, by Distribution Channel USD Million (2015-2020)
  • Table 69. Tetrahydrocannabinol Sales: by Application(Tons)
  • Table 70. Tetrahydrocannabinol Sales Chronic Pain , by Region Tons (2015-2020)
  • Table 71. Tetrahydrocannabinol Sales Mental Disorders , by Region Tons (2015-2020)
  • Table 72. Tetrahydrocannabinol Sales Arthritis , by Region Tons (2015-2020)
  • Table 73. Tetrahydrocannabinol Sales Migraine , by Region Tons (2015-2020)
  • Table 74. Tetrahydrocannabinol Sales Cancer , by Region Tons (2015-2020)
  • Table 75. Tetrahydrocannabinol Sales Other , by Region Tons (2015-2020)
  • Table 76. Tetrahydrocannabinol Sales: by Distribution Channel(Tons)
  • Table 77. Tetrahydrocannabinol Sales Hospital Pharmacy , by Region Tons (2015-2020)
  • Table 78. Tetrahydrocannabinol Sales Dispensaries , by Region Tons (2015-2020)
  • Table 79. Tetrahydrocannabinol Sales Online Pharmacy , by Region Tons (2015-2020)
  • Table 80. South America Tetrahydrocannabinol Sales, by Country Tons (2015-2020)
  • Table 81. South America Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 82. South America Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 83. Brazil Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 84. Brazil Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 85. Argentina Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 86. Argentina Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 87. Rest of South America Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 88. Rest of South America Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 89. Asia Pacific Tetrahydrocannabinol Sales, by Country Tons (2015-2020)
  • Table 90. Asia Pacific Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 91. Asia Pacific Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 92. China Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 93. China Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 94. Japan Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 95. Japan Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 96. India Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 97. India Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 98. South Korea Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 99. South Korea Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 100. Taiwan Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 101. Taiwan Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 102. Australia Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 103. Australia Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 104. Rest of Asia-Pacific Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 105. Rest of Asia-Pacific Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 106. Europe Tetrahydrocannabinol Sales, by Country Tons (2015-2020)
  • Table 107. Europe Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 108. Europe Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 109. Germany Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 110. Germany Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 111. France Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 112. France Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 113. Italy Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 114. Italy Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 115. United Kingdom Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 116. United Kingdom Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 117. Netherlands Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 118. Netherlands Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 119. Rest of Europe Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 120. Rest of Europe Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 121. MEA Tetrahydrocannabinol Sales, by Country Tons (2015-2020)
  • Table 122. MEA Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 123. MEA Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 124. Middle East Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 125. Middle East Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 126. Africa Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 127. Africa Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 128. North America Tetrahydrocannabinol Sales, by Country Tons (2015-2020)
  • Table 129. North America Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 130. North America Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 131. United States Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 132. United States Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 133. Canada Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 134. Canada Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 135. Mexico Tetrahydrocannabinol Sales, by Application Tons (2015-2020)
  • Table 136. Mexico Tetrahydrocannabinol Sales, by Distribution Channel Tons (2015-2020)
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Tetrahydrocannabinol: by Application(USD Million)
  • Table 148. Tetrahydrocannabinol Chronic Pain , by Region USD Million (2021-2026)
  • Table 149. Tetrahydrocannabinol Mental Disorders , by Region USD Million (2021-2026)
  • Table 150. Tetrahydrocannabinol Arthritis , by Region USD Million (2021-2026)
  • Table 151. Tetrahydrocannabinol Migraine , by Region USD Million (2021-2026)
  • Table 152. Tetrahydrocannabinol Cancer , by Region USD Million (2021-2026)
  • Table 153. Tetrahydrocannabinol Other , by Region USD Million (2021-2026)
  • Table 154. Tetrahydrocannabinol: by Distribution Channel(USD Million)
  • Table 155. Tetrahydrocannabinol Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 156. Tetrahydrocannabinol Dispensaries , by Region USD Million (2021-2026)
  • Table 157. Tetrahydrocannabinol Online Pharmacy , by Region USD Million (2021-2026)
  • Table 158. South America Tetrahydrocannabinol, by Country USD Million (2021-2026)
  • Table 159. South America Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 160. South America Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 161. Brazil Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 162. Brazil Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 163. Argentina Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 164. Argentina Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 165. Rest of South America Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 166. Rest of South America Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 167. Asia Pacific Tetrahydrocannabinol, by Country USD Million (2021-2026)
  • Table 168. Asia Pacific Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 169. Asia Pacific Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 170. China Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 171. China Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 172. Japan Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 173. Japan Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 174. India Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 175. India Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 176. South Korea Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 177. South Korea Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 178. Taiwan Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 179. Taiwan Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 180. Australia Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 181. Australia Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 182. Rest of Asia-Pacific Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 183. Rest of Asia-Pacific Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 184. Europe Tetrahydrocannabinol, by Country USD Million (2021-2026)
  • Table 185. Europe Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 186. Europe Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 187. Germany Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 188. Germany Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 189. France Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 190. France Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 191. Italy Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 192. Italy Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 193. United Kingdom Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 194. United Kingdom Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 195. Netherlands Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 196. Netherlands Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 197. Rest of Europe Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 198. Rest of Europe Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 199. MEA Tetrahydrocannabinol, by Country USD Million (2021-2026)
  • Table 200. MEA Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 201. MEA Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 202. Middle East Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 203. Middle East Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 204. Africa Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 205. Africa Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 206. North America Tetrahydrocannabinol, by Country USD Million (2021-2026)
  • Table 207. North America Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 208. North America Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 209. United States Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 210. United States Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 211. Canada Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 212. Canada Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 213. Mexico Tetrahydrocannabinol, by Application USD Million (2021-2026)
  • Table 214. Mexico Tetrahydrocannabinol, by Distribution Channel USD Million (2021-2026)
  • Table 215. Tetrahydrocannabinol Sales: by Application(Tons)
  • Table 216. Tetrahydrocannabinol Sales Chronic Pain , by Region Tons (2021-2026)
  • Table 217. Tetrahydrocannabinol Sales Mental Disorders , by Region Tons (2021-2026)
  • Table 218. Tetrahydrocannabinol Sales Arthritis , by Region Tons (2021-2026)
  • Table 219. Tetrahydrocannabinol Sales Migraine , by Region Tons (2021-2026)
  • Table 220. Tetrahydrocannabinol Sales Cancer , by Region Tons (2021-2026)
  • Table 221. Tetrahydrocannabinol Sales Other , by Region Tons (2021-2026)
  • Table 222. Tetrahydrocannabinol Sales: by Distribution Channel(Tons)
  • Table 223. Tetrahydrocannabinol Sales Hospital Pharmacy , by Region Tons (2021-2026)
  • Table 224. Tetrahydrocannabinol Sales Dispensaries , by Region Tons (2021-2026)
  • Table 225. Tetrahydrocannabinol Sales Online Pharmacy , by Region Tons (2021-2026)
  • Table 226. South America Tetrahydrocannabinol Sales, by Country Tons (2021-2026)
  • Table 227. South America Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 228. South America Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 229. Brazil Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 230. Brazil Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 231. Argentina Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 232. Argentina Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 233. Rest of South America Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 234. Rest of South America Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 235. Asia Pacific Tetrahydrocannabinol Sales, by Country Tons (2021-2026)
  • Table 236. Asia Pacific Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 237. Asia Pacific Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 238. China Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 239. China Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 240. Japan Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 241. Japan Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 242. India Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 243. India Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 244. South Korea Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 245. South Korea Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 246. Taiwan Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 247. Taiwan Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 248. Australia Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 249. Australia Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 250. Rest of Asia-Pacific Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 251. Rest of Asia-Pacific Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 252. Europe Tetrahydrocannabinol Sales, by Country Tons (2021-2026)
  • Table 253. Europe Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 254. Europe Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 255. Germany Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 256. Germany Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 257. France Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 258. France Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 259. Italy Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 260. Italy Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 261. United Kingdom Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 262. United Kingdom Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 263. Netherlands Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 264. Netherlands Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 265. Rest of Europe Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 266. Rest of Europe Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 267. MEA Tetrahydrocannabinol Sales, by Country Tons (2021-2026)
  • Table 268. MEA Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 269. MEA Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 270. Middle East Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 271. Middle East Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 272. Africa Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 273. Africa Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 274. North America Tetrahydrocannabinol Sales, by Country Tons (2021-2026)
  • Table 275. North America Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 276. North America Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 277. United States Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 278. United States Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 279. Canada Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 280. Canada Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 281. Mexico Tetrahydrocannabinol Sales, by Application Tons (2021-2026)
  • Table 282. Mexico Tetrahydrocannabinol Sales, by Distribution Channel Tons (2021-2026)
  • Table 283. Research Programs/Design for This Report
  • Table 284. Key Data Information from Secondary Sources
  • Table 285. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tetrahydrocannabinol: by Application USD Million (2015-2020)
  • Figure 5. Global Tetrahydrocannabinol: by Distribution Channel USD Million (2015-2020)
  • Figure 6. South America Tetrahydrocannabinol Share (%), by Country
  • Figure 7. Asia Pacific Tetrahydrocannabinol Share (%), by Country
  • Figure 8. Europe Tetrahydrocannabinol Share (%), by Country
  • Figure 9. MEA Tetrahydrocannabinol Share (%), by Country
  • Figure 10. North America Tetrahydrocannabinol Share (%), by Country
  • Figure 11. Global Tetrahydrocannabinol: by Application Tons (2015-2020)
  • Figure 12. Global Tetrahydrocannabinol: by Distribution Channel Tons (2015-2020)
  • Figure 13. South America Tetrahydrocannabinol Share (%), by Country
  • Figure 14. Asia Pacific Tetrahydrocannabinol Share (%), by Country
  • Figure 15. Europe Tetrahydrocannabinol Share (%), by Country
  • Figure 16. MEA Tetrahydrocannabinol Share (%), by Country
  • Figure 17. North America Tetrahydrocannabinol Share (%), by Country
  • Figure 18. Global Tetrahydrocannabinol share by Players 2020 (%)
  • Figure 19. Global Tetrahydrocannabinol share by Players (Top 3) 2020(%)
  • Figure 20. Global Tetrahydrocannabinol share by Players (Top 5) 2020(%)
  • Figure 21. BCG Matrix for key Companies
  • Figure 22. MedReleaf Corporation (Canada) Revenue, Net Income and Gross profit
  • Figure 23. MedReleaf Corporation (Canada) Revenue: by Geography 2020
  • Figure 24. Aurora Cannabis Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 25. Aurora Cannabis Inc. (Canada) Revenue: by Geography 2020
  • Figure 26. BOL Pharma (Israel) Revenue, Net Income and Gross profit
  • Figure 27. BOL Pharma (Israel) Revenue: by Geography 2020
  • Figure 28. Tilray (Canada) Revenue, Net Income and Gross profit
  • Figure 29. Tilray (Canada) Revenue: by Geography 2020
  • Figure 30. Medreleaf Corporation (Canada) Revenue, Net Income and Gross profit
  • Figure 31. Medreleaf Corporation (Canada) Revenue: by Geography 2020
  • Figure 32. Aurora Cannabis, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 33. Aurora Cannabis, Inc. (Canada) Revenue: by Geography 2020
  • Figure 34. Green Relief Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 35. Green Relief Inc. (Canada) Revenue: by Geography 2020
  • Figure 36. Canopy Growth Corporation (Canada) Revenue, Net Income and Gross profit
  • Figure 37. Canopy Growth Corporation (Canada) Revenue: by Geography 2020
  • Figure 38. Insys Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Insys Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 40. Aphria, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 41. Aphria, Inc. (Canada) Revenue: by Geography 2020
  • Figure 42. Global Tetrahydrocannabinol: by Application USD Million (2021-2026)
  • Figure 43. Global Tetrahydrocannabinol: by Distribution Channel USD Million (2021-2026)
  • Figure 44. South America Tetrahydrocannabinol Share (%), by Country
  • Figure 45. Asia Pacific Tetrahydrocannabinol Share (%), by Country
  • Figure 46. Europe Tetrahydrocannabinol Share (%), by Country
  • Figure 47. MEA Tetrahydrocannabinol Share (%), by Country
  • Figure 48. North America Tetrahydrocannabinol Share (%), by Country
  • Figure 49. Global Tetrahydrocannabinol: by Application Tons (2021-2026)
  • Figure 50. Global Tetrahydrocannabinol: by Distribution Channel Tons (2021-2026)
  • Figure 51. South America Tetrahydrocannabinol Share (%), by Country
  • Figure 52. Asia Pacific Tetrahydrocannabinol Share (%), by Country
  • Figure 53. Europe Tetrahydrocannabinol Share (%), by Country
  • Figure 54. MEA Tetrahydrocannabinol Share (%), by Country
  • Figure 55. North America Tetrahydrocannabinol Share (%), by Country
List of companies from research coverage that are profiled in the study
  • MedReleaf Corporation (Canada)
  • Aurora Cannabis Inc. (Canada)
  • BOL Pharma (Israel)
  • Tilray (Canada)
  • Medreleaf Corporation (Canada)
  • Aurora Cannabis, Inc. (Canada)
  • Green Relief Inc. (Canada)
  • Canopy Growth Corporation (Canada)
  • Insys Therapeutics, Inc. (United States)
  • Aphria, Inc. (Canada)
Additional players considered in the study are as follows:
MGC Pharmaceuticals Limited (Australia) , GW Pharmaceuticals, plc (United Kingdom) , Medical Marijuana Inc. (United States)
Select User Access Type

Key Highlights of Report


Nov 2021 235 Pages 77 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Tetrahydrocannabinol Market Quantitative research analysis
Global Tetrahydrocannabinol Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Tetrahydrocannabinol market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Tetrahydrocannabinol market are MedReleaf Corporation (Canada), Aurora Cannabis Inc. (Canada), BOL Pharma (Israel), Tilray (Canada), Medreleaf Corporation (Canada), Aurora Cannabis, Inc. (Canada), Green Relief Inc. (Canada), Canopy Growth Corporation (Canada), Insys Therapeutics, Inc. (United States) and Aphria, Inc. (Canada), to name a few.
North America is dominating the Tetrahydrocannabinol Market.

Know More About Global Tetrahydrocannabinol Market Report?

Have a Query? Click Here

Other Related Reports

Dermatology Drugs Comprehensive Study by Type (Prescription-Based Drugs, Over-the-Counter Drugs), Application (Psoriasis, Skin Infections, Acne, Dermatitis, Other), Forms (Tablets, External Use, Inje...
$ 3500
Coenzyme A Comprehensive Study by Type (Lithium Salt, Sodium Salt, Free Acid, Others), Application (Biotechnology Research, Dietary Supplement, Therapeutic, Others) Players and Region - Global Market...
$ 3500
Acid Resistant Capsules Comprehensive Study by Type (Gelatin Acid Resistant Capsules, Vegan Acid Resistant Capsules, Pullulan Acid Resistant Capsules, HPMC Acid Resistant Capsules), Application (Heal...
$ 3650
Cannabidiol Cbd Comprehensive Study by Type (Marijuana-Derived Cannabidiol Products, Hemp-Derived Cannabidiol Products), Application (Personal Care & Cosmetics, Pharmaceutical (Anxiety, Fibromyalgia ...
$ 3750
Retrovirus Testing Comprehensive Study by Application (Hospital, Diagnostic Laboratory, Clinic), Sample (Body Fluid, Serum, Blood, Cell), Test Type (Infectivity Assay, Serological Test, Radio-immunoa...
$ 3800
Talazoparib Comprehensive Study by Type (0.25mg Capsules, 1mg Capsules), Application (Hospital, Drug Center, Clinic), Disease Type (Treat Prostate Cancer, Breast Cancers, Endometrial Cancer, Uterine ...
$ 3450